1
|
Rathore M, Girard C, Ohanna M, Tichet M, Ben Jouira R, Garcia E, Larbret F, Gesson M, Audebert S, Lacour JP, Montaudié H, Prod'Homme V, Tartare-Deckert S, Deckert M. Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)/NF-κB signaling pathway. Oncogene 2019; 38:5873-5889. [PMID: 31253871 DOI: 10.1038/s41388-019-0848-9] [Citation(s) in RCA: 55] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2018] [Revised: 03/30/2019] [Accepted: 04/28/2019] [Indexed: 01/23/2023]
Abstract
Cutaneous melanoma is one of the most aggressive cancers characterized by a high plasticity, a propensity for metastasis, and drug resistance. Melanomas are composed of phenotypically diverse subpopulations of tumor cells with heterogeneous molecular profiles that reflect intrinsic invasive abilities. In an attempt to identify novel factors of the melanoma invasive cell state, we previously investigated the nature of the invasive secretome by using a comparative proteomic approach. Here, we have extended this analysis to show that PTX3, an acute phase inflammatory glycoprotein, is one such factor secreted by invasive melanoma to promote tumor cell invasiveness. Elevated PTX3 production was observed in the population of MITFlow invasive cells but not in the population of MITFhigh differentiated melanoma cells. Consistently, MITF knockdown increased PTX3 expression in MITFhigh proliferative and poorly invasive cells. High levels of PTX3 were found in tissues and blood of metastatic melanoma patients, and in BRAF inhibitor-resistant melanoma cells displaying a mesenchymal invasive MITFlow phenotype. Genetic silencing of PTX3 in invasive melanoma cells dramatically impaired migration and invasion in vitro and in experimental lung extravasation assay in xenografted mice. In contrast, addition of melanoma-derived or recombinant PTX3, or expression of PTX3 enhanced motility of low migratory cells. Mechanistically, autocrine production of PTX3 by melanoma cells triggered an IKK/NFκB signaling pathway that promotes migration, invasion, and expression of the EMT factor TWIST1. Finally, we found that TLR4 and MYD88 knockdown inhibited PTX3-induced melanoma cell migration, suggesting that PTX3 functions through a TLR4-dependent pathway. Our work reveals that tumor-derived PTX3 contributes to melanoma cell invasion via targetable inflammation-related pathways. In addition to providing new insights into the biology of melanoma invasive behavior, this study underscores the notion that secreted PTX3 represents a potential biomarker and therapeutic target in a subpopulation of MITFlow invasive and/or refractory melanoma.
Collapse
Affiliation(s)
- M Rathore
- Université Côte d'Azur, INSERM, C3M, Nice, France
- Equipe labellisée Ligue Contre le Cancer 2016, Nice, France
- The Hormel Institute, University of Minnesota, Austin, MN, USA
| | - C Girard
- Université Côte d'Azur, INSERM, C3M, Nice, France
- Equipe labellisée Ligue Contre le Cancer 2016, Nice, France
| | - M Ohanna
- Université Côte d'Azur, INSERM, C3M, Nice, France
- Equipe labellisée Ligue Contre le Cancer 2016, Nice, France
| | - M Tichet
- Université Côte d'Azur, INSERM, C3M, Nice, France
- Laboratory of Translational Oncology, ISREC, EPFL, Lausanne, Switzerland
| | - R Ben Jouira
- Université Côte d'Azur, INSERM, C3M, Nice, France
| | - E Garcia
- Université Côte d'Azur, INSERM, C3M, Nice, France
| | - F Larbret
- Université Côte d'Azur, INSERM, C3M, Nice, France
- Equipe labellisée Ligue Contre le Cancer 2016, Nice, France
| | - M Gesson
- Université Côte d'Azur, INSERM, C3M, Nice, France
| | - S Audebert
- Aix-Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France
| | - J-P Lacour
- Université Côte d'Azur, CHU Nice, Nice, France
| | - H Montaudié
- Université Côte d'Azur, CHU Nice, Nice, France
| | - V Prod'Homme
- Université Côte d'Azur, INSERM, C3M, Nice, France
- Equipe labellisée Ligue Contre le Cancer 2016, Nice, France
| | - S Tartare-Deckert
- Université Côte d'Azur, INSERM, C3M, Nice, France.
- Equipe labellisée Ligue Contre le Cancer 2016, Nice, France.
| | - M Deckert
- Université Côte d'Azur, INSERM, C3M, Nice, France.
- Equipe labellisée Ligue Contre le Cancer 2016, Nice, France.
| |
Collapse
|
2
|
Deckert M, Prod'Homme V. [SH3BP2 heterozygous mutation amplifies macrophage inflammatory responses to infection in a mouse model of cherubism]. Med Sci (Paris) 2015; 31:589-91. [PMID: 26152156 DOI: 10.1051/medsci/20153106005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Marcel Deckert
- Centre méditerranéen de médecine moléculaire (C3M), Inserm, U1065, équipe microenvironnement, signalisation et cancer, bâtiment universitaire ARCHIMED, 151, route Saint Antoine de Ginestière, 06204 Nice Cedex 03, France - Université de Nice Sophia Antipolis, faculté de médecine, laboratoire d'excellence Signalife, 06103 Nice, France
| | - Virginie Prod'Homme
- Centre méditerranéen de médecine moléculaire (C3M), Inserm, U1065, équipe microenvironnement, signalisation et cancer, bâtiment universitaire ARCHIMED, 151, route Saint Antoine de Ginestière, 06204 Nice Cedex 03, France - Université de Nice Sophia Antipolis, faculté de médecine, laboratoire d'excellence Signalife, 06103 Nice, France
| |
Collapse
|
3
|
Tichet M, Prod'Homme V, Fenouille N, Ambrosetti D, Mallavialle A, Cerezo M, Ohanna M, Audebert S, Rocchi S, Giacchero D, Boukari F, Allegra M, Chambard JC, Lacour JP, Michiels JF, Borg JP, Deckert M, Tartare-Deckert S. Tumour-derived SPARC drives vascular permeability and extravasation through endothelial VCAM1 signalling to promote metastasis. Nat Commun 2015; 6:6993. [PMID: 25925867 DOI: 10.1038/ncomms7993] [Citation(s) in RCA: 134] [Impact Index Per Article: 14.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2015] [Accepted: 03/23/2015] [Indexed: 12/20/2022] Open
Abstract
Disruption of the endothelial barrier by tumour-derived secreted factors is a critical step in cancer cell extravasation and metastasis. Here, by comparative proteomic analysis of melanoma secretomes, we identify the matricellular protein SPARC as a novel tumour-derived vascular permeability factor. SPARC deficiency abrogates tumour-initiated permeability of lung capillaries and prevents extravasation, whereas SPARC overexpression enhances vascular leakiness, extravasation and lung metastasis. SPARC-induced paracellular permeability is dependent on the endothelial VCAM1 receptor and p38 MAPK signalling. Blocking VCAM1 impedes melanoma-induced endothelial permeability and extravasation. The clinical relevance of our findings is highlighted by high levels of SPARC detected in tumour from human pulmonary melanoma lesions. Our study establishes tumour-produced SPARC and VCAM1 as regulators of cancer extravasation, revealing a novel targetable interaction for prevention of metastasis.
Collapse
Affiliation(s)
- Mélanie Tichet
- 1] INSERM, U1065, Microenvironnement, Signalisation et Cancer, Centre Méditerranéen de Médecine Moléculaire (C3M), 151 Route de Saint-Antoine de Ginestière, BP 23194, 06204 Nice, France [2] Université de Nice Sophia Antipolis, Faculté de Médecine, 06107 Nice, France
| | - Virginie Prod'Homme
- 1] INSERM, U1065, Microenvironnement, Signalisation et Cancer, Centre Méditerranéen de Médecine Moléculaire (C3M), 151 Route de Saint-Antoine de Ginestière, BP 23194, 06204 Nice, France [2] Université de Nice Sophia Antipolis, Faculté de Médecine, 06107 Nice, France
| | - Nina Fenouille
- 1] INSERM, U1065, Microenvironnement, Signalisation et Cancer, Centre Méditerranéen de Médecine Moléculaire (C3M), 151 Route de Saint-Antoine de Ginestière, BP 23194, 06204 Nice, France [2] Université de Nice Sophia Antipolis, Faculté de Médecine, 06107 Nice, France
| | - Damien Ambrosetti
- 1] Université de Nice Sophia Antipolis, Faculté de Médecine, 06107 Nice, France [2] Centre Hospitalier Universitaire (CHU) de Nice, Hôpital Pasteur, Laboratoire Central d'Anatomo Pathologie, 06002 Nice, France
| | - Aude Mallavialle
- 1] INSERM, U1065, Microenvironnement, Signalisation et Cancer, Centre Méditerranéen de Médecine Moléculaire (C3M), 151 Route de Saint-Antoine de Ginestière, BP 23194, 06204 Nice, France [2] Université de Nice Sophia Antipolis, Faculté de Médecine, 06107 Nice, France
| | - Michael Cerezo
- 1] Université de Nice Sophia Antipolis, Faculté de Médecine, 06107 Nice, France [2] INSERM, U1065, Biologie et Pathologies des Mélanocytes, C3M, 151 Route de Saint-Antoine de Ginestière, BP 23194, 06204 Nice, France
| | - Mickaël Ohanna
- 1] Université de Nice Sophia Antipolis, Faculté de Médecine, 06107 Nice, France [2] INSERM, U1065, Biologie et Pathologies des Mélanocytes, C3M, 151 Route de Saint-Antoine de Ginestière, BP 23194, 06204 Nice, France
| | - Stéphane Audebert
- CRCM, INSERM U1068, Institut Paoli-Calmettes, Aix-Marseille Université, UM105; CNRS UMR7258, BP 30059, 13273 Marseille, France
| | - Stéphane Rocchi
- 1] Université de Nice Sophia Antipolis, Faculté de Médecine, 06107 Nice, France [2] INSERM, U1065, Biologie et Pathologies des Mélanocytes, C3M, 151 Route de Saint-Antoine de Ginestière, BP 23194, 06204 Nice, France
| | - Damien Giacchero
- 1] Université de Nice Sophia Antipolis, Faculté de Médecine, 06107 Nice, France [2] CHU de Nice, Hôpital Archet 2, Service de Dermatologie, 06202 Nice, France
| | - Fériel Boukari
- 1] INSERM, U1065, Microenvironnement, Signalisation et Cancer, Centre Méditerranéen de Médecine Moléculaire (C3M), 151 Route de Saint-Antoine de Ginestière, BP 23194, 06204 Nice, France [2] Université de Nice Sophia Antipolis, Faculté de Médecine, 06107 Nice, France [3] CHU de Nice, Hôpital Archet 2, Service de Dermatologie, 06202 Nice, France
| | - Maryline Allegra
- 1] Université de Nice Sophia Antipolis, Faculté de Médecine, 06107 Nice, France [2] INSERM, U1065, Biologie et Pathologies des Mélanocytes, C3M, 151 Route de Saint-Antoine de Ginestière, BP 23194, 06204 Nice, France
| | - Jean-Claude Chambard
- 1] Université de Nice Sophia Antipolis, Faculté de Médecine, 06107 Nice, France [2] INSERM, U1091, CNRS, UMR 7277, iBV, Faculté des Sciences, Parc Valrose, 06108 Nice, France
| | - Jean-Philippe Lacour
- 1] Université de Nice Sophia Antipolis, Faculté de Médecine, 06107 Nice, France [2] CHU de Nice, Hôpital Archet 2, Service de Dermatologie, 06202 Nice, France
| | - Jean-François Michiels
- 1] Université de Nice Sophia Antipolis, Faculté de Médecine, 06107 Nice, France [2] Centre Hospitalier Universitaire (CHU) de Nice, Hôpital Pasteur, Laboratoire Central d'Anatomo Pathologie, 06002 Nice, France
| | - Jean-Paul Borg
- CRCM, INSERM U1068, Institut Paoli-Calmettes, Aix-Marseille Université, UM105; CNRS UMR7258, BP 30059, 13273 Marseille, France
| | - Marcel Deckert
- 1] INSERM, U1065, Microenvironnement, Signalisation et Cancer, Centre Méditerranéen de Médecine Moléculaire (C3M), 151 Route de Saint-Antoine de Ginestière, BP 23194, 06204 Nice, France [2] Université de Nice Sophia Antipolis, Faculté de Médecine, 06107 Nice, France
| | - Sophie Tartare-Deckert
- 1] INSERM, U1065, Microenvironnement, Signalisation et Cancer, Centre Méditerranéen de Médecine Moléculaire (C3M), 151 Route de Saint-Antoine de Ginestière, BP 23194, 06204 Nice, France [2] Université de Nice Sophia Antipolis, Faculté de Médecine, 06107 Nice, France
| |
Collapse
|